UHLMANN PRICE SECURITIES’s AbbVie ABBV Stock Holding History

UHLMANN PRICE SECURITIES’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.71M	Buy	12,875 +7,523	+141%	+$1.67M	0.18%	22
2025 Q4	$1.22M	Buy	5,352 +19	+0.4%	+$4.33K	0.73%	34
2025 Q3	$1.23M	Buy	5,333 +203	+4%	+$41.3K	0.75%	33
2025 Q2	$952K	Buy	5,130 +116	+2%	+$21.6K	0.68%	36
2025 Q1	$1.05M	Sell	5,014 -13	-0.3%	-$2.53K	0.77%	32
2024 Q4	$893K	Buy	5,027 +27	+0.5%	+$4.96K	0.67%	36
2024 Q3	$987K	Buy	+5,000	New	+$933K	0.78%	29

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UHLMANN PRICE SECURITIES's ABBV Position: Q1 2026 in Review

UHLMANN PRICE SECURITIES increased its AbbVie (ABBV) stake by 141% in Q1 2026, buying an estimated $1.67M and bringing the position to 12,875 shares worth $2.71M. The position accounts for 0.18% of the portfolio, ranked #22.

UHLMANN PRICE SECURITIES first reported a position in ABBV in Q3 2024 and has held it in 7 quarters since. 4,074 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

UHLMANN PRICE SECURITIES held 12,875 shares of AbbVie worth $2.71M as of Q1 2026.
UHLMANN PRICE SECURITIES bought 7,523 AbbVie shares in Q1 2026, an estimated $1.67M.
AbbVie made up 0.18% of UHLMANN PRICE SECURITIES's portfolio in Q1 2026, its #22 holding.
UHLMANN PRICE SECURITIES first reported a position in AbbVie in Q3 2024 and has held it in 7 quarters since.
4,074 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on UHLMANN PRICE SECURITIES's 13F filing for Q1 2026, filed 16 Apr 2026.